-

Evecxia Therapeutics ACCESS CHINA Partnering Forum

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics—the first company dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification to treat CNS disorders—today announced Dr. Jacob Pade Ramsøe Jacobsen, the Co-Founder & Chief Executive Officer of Evecxia Therapeutics, Inc., will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024.

Link to ACCESS CHINA.

About Evecxia Therapeutics

Evecxia is the first company dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification to treat CNS disorders. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression and obsessive-compulsive disorder (OCD) when first-line serotonin reuptake inhibitor (SSRI/SNRI) antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy for patients hospitalized for acute suicidal crisis.

For additional information about Evecxia, please visit www.evecxia.com.

Contacts

Jacob Jacobsen, CEO
Evecxia Therapeutics, Inc.
Info@evecxia.com

Industry:

Evecxia Therapeutics

Release Versions
English

Contacts

Jacob Jacobsen, CEO
Evecxia Therapeutics, Inc.
Info@evecxia.com

More News From Evecxia Therapeutics

Evecxia Doses First Patient in Phase 1b Brain Target Engagement Study of Serotonin Synthesis Amplification Therapy

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics, Inc.—a clinical-stage neuroscience company developing a novel class of Serotonin Synthesis Amplification therapies—today announced that the first patient has been dosed in a Phase 1b randomized, placebo-controlled target-engagement study in patients with depression and treated with serotonin reuptake inhibitor antidepressants. This placebo-controlled Phase 1b trial is designed to confirm the pharmacokinetic/pharmacodynamic (PK...

Evecxia Provides Financing & Corporate Updates Including Plans for an EVX-101 Proof-of-Concept Phase 2 Clinical Study in Obsessive-Compulsive Disorder (OCD) Responding Inadequately to First-line Therapies

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it has completed a new financing round, with gross proceeds of approximately $5.0 million. This financing will fund clinical, non-clinical and CMC activities in anticipation of our plans to initiate an adequate, placebo-controlled Phase 2 clinical study evaluating EVX-101, as adjunctive thera...

Evecxia Therapeutics Announces Appointment Of C.R. Sincock II To The Board Of Directors

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Evecxia Therapeutics today announced the appointment of C.R. Sincock II to the Board of Directors, effective February 11, 2025. Mr. Sincock is the founder and managing director of Transhuman Capital, a venture firm investing in the development of therapeutics to solve humanity’s biggest medical challenges. Transhuman Capital is an investor in Evecxia. “I am thrilled to join Evecxia Therapeutics’ Board at a pivotal moment when the company is poised...
Back to Newsroom